(+)-VINCRISTINE
Recurrence
Kyorin UniversitySmall moleculePhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 89/ 100
Competitive context
3 Active assets in the Recurrence cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Psma-Hbed-Cc Novartis Pharmaceuticals | Phase 3 | B |
Capecitabine Amsterdam UMC, location VUmc | Phase 3 | B |
Irinotecan Amsterdam UMC, location VUmc | Phase 3 | B |
Epirubicin Asha Nayak | Phase 1/2 | CC |
Cyclophosphamide Asha Nayak | Phase 1/2 | CC |
Same molecule, other indications
(+)-VINCRISTINE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →